Spots Global Cancer Trial Database for bronchial neoplasms
Every month we try and update this database with for bronchial neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Icotinib for Completed Resected IB NSCLC With EGFR Mutation | NCT02264210 | Lung Neoplasms Squamous Cell L... Adenocarcinoma ... Adenosquamous C... Large Cell Lung... Bronchial Neopl... Stage IB Non-sm... | Icotinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | NCT04974879 | Carcinoma, Non-... | Osimertinib Ora... | 18 Years - 80 Years | Qingdao Central Hospital | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 | Carcinoma, Non-... | Napabucasin Paclitaxel | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 | Carcinoma, Non-... | Napabucasin Paclitaxel | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| Evaluation of a New Open Source Virtual Bronchoscope Navigation System | NCT03745859 | Bronchial Neopl... | Fraxinus VBN sy... | 18 Years - | Norwegian University of Science and Technology | |
| A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | NCT02134015 | Lung Cancer Non-small Cell ... | Patritumab Erlotinib Placebo | 20 Years - | Daiichi Sankyo | |
| A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy | NCT05941897 | Advanced or Met... | Ceralasertib Durvalumab | 18 Years - | AstraZeneca | |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial | NCT03402048 | Stage IV, NSCLC Lung Neoplasms Bronchial Neopl... Carcinoma, Bron... Lung Diseases Neoplasms Respiratory Tra... Respiratory Tra... Thoracic Neopla... | Carboplatin Gemcitabine Pemetrexed Docetaxel Vinorelbine | 70 Years - | University of Turin, Italy | |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NCT02909452 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | NCT04974879 | Carcinoma, Non-... | Osimertinib Ora... | 18 Years - 80 Years | Qingdao Central Hospital | |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | NCT04512430 | Non Small Cell ... EGFR Gene Mutat... | Atezolizumab Bevacizumab Carboplatin Pemetrexed | 18 Years - | Fundación GECP | |
| Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer | NCT02288026 | Stage IA Non-sm... Adenocarcinoma ... Squamous Cell L... | 60 Years - 80 Years | Capital Medical University | ||
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | NCT05153408 | Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ... | BLU-701 osimertinib carboplatin pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | NCT05241873 | Lung Neoplasm M... Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... EGFR Exon 20 Mu... EGFR Exon 20 In... EGFR Activating... Antineoplastic ... Metastatic Lung... Brain Metastase... EGFR-mutated NS... EGFR Atypical M... | BLU-451 Carboplatin Pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | NCT05104281 | Carcinoma, Non-... | osimertinib ora... | 18 Years - 90 Years | Qingdao Central Hospital | |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | NCT02897778 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Neoplasm... Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Placebo | 18 Years - | Syndax Pharmaceuticals | |
| Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT | NCT01261585 | Bronchial Neopl... Carcinoma, Non-... | 18 Years - 75 Years | Centre Henri Becquerel | ||
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | NCT05104281 | Carcinoma, Non-... | osimertinib ora... | 18 Years - 90 Years | Qingdao Central Hospital | |
| Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | NCT01594398 | Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept... | entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane | 18 Years - 90 Years | Syndax Pharmaceuticals | |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | NCT02904954 | Carcinoma, Non-... | Durvalumab Durvalumab plus... | 18 Years - | Weill Medical College of Cornell University | |
| A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | NCT05110196 | Non-Small Cell ... | Capmatinib 150 ... Capmatinib 200 ... | 18 Years - 99 Years | Novartis | |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | NCT05110196 | Non-Small Cell ... | Capmatinib 150 ... Capmatinib 200 ... | 18 Years - 99 Years | Novartis | |
| Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC | NCT06376084 | Carcinoma, Non-... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... | 18 Years - | AstraZeneca | ||
| Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients | NCT02804100 | Carcinoma, Non-... Bronchial Neopl... Carcinoma, Bron... Lung Diseases Lung Neoplasms | 18 Years - | Wenzhou Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
